Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The overall goal of this research program is to evaluate the effectiveness of a Technology-Enabled Collaborative Care program. In this study, we examine the feasibility of such a program, called the Technology-Enabled Collaborative Care (TECC) for type 2 diabetes designed to support patients with diabetes and mental health concerns during COVID-19.
Description: The primary outcome in this study is feasibility, specifically process outcomes. This includes assessing recruitment number
Measure: Feasibility - Recruitment Numbers Time: Through the study completion, an average of 4 monthsDescription: The primary outcome in this study is feasibility, specifically process outcomes. This includes participant characteristics
Measure: Feasibility - Participant characteristics Time: up to 8-weeksDescription: The primary outcome in this study is feasibility, specifically process outcomes. This includes participant retention rate (e.g., defined by time between first and last visit)
Measure: Feasibility - Participant Engagement (retention rate) Time: up to 8-weeksDescription: The primary outcome in this study is feasibility, specifically process outcomes. This includes intensity (e.g., number of session participants attend)
Measure: Feasibility - Participant Engagement (intensity) Time: up to 8-weeksDescription: The primary outcome in this study is feasibility, specifically process outcomes. This includes drop out (consented/enrolled but did not attend first one-on-one)
Measure: Feasibility - Participant Engagement (drop out) Time: up to 8-weeksDescription: The primary outcome in this study is feasibility, specifically process outcomes. This includes the amount of time a coach spends per interaction
Measure: Feasibility - Delivery of Intervention (Time with coach) Time: up to 8-weeksDescription: The primary outcome in this study is feasibility, specifically process outcomes. This includes the mode of the interaction (i.e., virtual, telephone or both)
Measure: Feasibility - Delivery of Intervention (Mode of interaction) Time: up to 12-weeksDescription: The primary outcome in this study is feasibility, specifically process outcomes. This includes what strategies are used by the coach (i.e., educational, psychosocial support, behaviour modifications, or case management/monitoring)
Measure: Feasibility - Delivery of Intervention (Coach strategies) Time: up to 12-weeksDescription: The secondary outcome consists of study participant experience/satisfaction.
Measure: Study Participant experience and satisfaction via semi-structured interview Time: up to 8-weeksDescription: The secondary outcome consists of Care Coordinator experience and satisfaction.
Measure: Care Coordinator experience and satisfaction via semi-structured interview Time: up to 8-weeksDescription: The secondary outcome consists of Virtual Care Team experience and satisfaction.
Measure: Virtual Care Team experience and satisfaction via semi-structured interview Time: up to 8-weeksDescription: The exploratory outcomes will include Health Behaviour metrics via International Physical Activity Questionnaire). Individual scores per question, the higher the score means the higher the level of physical activity.
Measure: Exploratory Outcome - Health Behaviour metrics (physical activity) Time: up to 4-weeksDescription: The exploratory outcomes will include Health Behaviour metrics (via Mediterranean Diet Adherence Screener Modified (MEDAS modified)
Measure: Exploratory Outcome - Health Behaviour metrics (diet) Time: up to 4-weeksDescription: The exploratory outcomes will include Health Behaviour metrics (via readiness to change ruler (smoking, alcohol, nutrition, physical activity). Minimum score: 0; maximum score: 10; higher score represented a better outcome.
Measure: Exploratory Outcome - Health Behaviour metrics (confidence/importance to change behaviour) Time: up to 12-weeksDescription: The exploratory outcomes will include substance use (via GAINS-SS (Global Appraisal of Individual Needs- Short Screener). Minimum score: 0; maximum score: 20; higher score represented a worse outcome.
Measure: Exploratory Outcome - Substance Use (GAINS-SS) Time: up to 12-weeksDescription: The exploratory outcomes will include substance use (Alcohol Use Disorders Identification Test (AUDIT); Minimum score: 0; maximum score: 40; higher score represented a worse outcome.
Measure: Exploratory Outcome - Substance Use (alcohol) Time: up to 12-weeksDescription: The exploratory outcomes will include substance use (via heaviness of smoking index - 2 items out of Fagerstrom test for nicotine dependence (FTND)); Minimum score: 0; maximum score: 6; higher score represented a worse outcome.
Measure: Exploratory Outcome - Substance Use Time: up to 12-weeksDescription: The exploratory outcomes will include Mental Health measures (via Patient Health Questionnaire (PHQ-9)). Minimum score: 0; maximum score: 27; higher score represented a worse outcome.
Measure: Exploratory Outcome - Mental Health (depression) Time: up to 12-weeksDescription: The exploratory outcomes will include Mental Health measures via Generalized Anxiety Disorder-7 (GAD-7). Minimum score: 0; maximum score: 21; higher score represented a worse outcome.
Measure: Exploratory Outcome - Mental Health (Anxiety) Time: up to 12-weeksDescription: The exploratory outcomes will include Mental Health measures via Diabetes awareness and insight scale. Minimum score: 0; maximum score: 10; higher score represented a better outcome.
Measure: Exploratory Outcome - Mental Health (Diabetes awareness/insight) Time: up to 12-weeksDescription: The exploratory outcomes will include Mental Health measures via Diabetes Distress Scale. Minimum score: 0; maximum score: 6; higher score represented a worse outcome.
Measure: Exploratory Outcome - Mental Health (Diabetes Distress) Time: up to 12-weeksDescription: The exploratory outcomes will include Mental Health measures via perceived stress scale (PSS). Minimum score: 0; maximum score: 40; higher score represented a worse outcome (i.e., higher perceived stress).
Measure: Exploratory Outcome - Mental Health (Stress) Time: up to 12-weeksDescription: The exploratory outcomes will include quality of life (via European Quality of Life - 5 Dimensions scale - EQ5D). Minimum score: 0; maximum score: 100; higher score represented a better outcome.
Measure: Exploratory Outcome - Quality of Life Time: up to 12-weeksDescription: The exploratory outcomes will include quality of life (via Verona satisfaction scale). Minimum score: 0; higher score represented a better outcome.
Measure: Exploratory Outcome - Quality of Life Time: up to 12-weeksDescription: self-report
Measure: Exploratory Outcome - Waist circumference Time: up to 12-weeksDescription: self-report
Measure: Exploratory Outcome - BMI (height/weight) Time: up to 12-weeksDescription: self-report
Measure: Exploratory Outcome - Blood pressure Time: up to 12-weeksDescription: list
Measure: Exploratory Outcome - Current medication Time: up to 12-weeksDescription: Hemoglobin A1C levels
Measure: Exploratory Outcome - Blood work Time: up to 12-weeksDescription: Brief Pain Inventory-sf. Minimum score: 0; maximum score: 10; higher score represented a worse outcome (i.e., more pain).
Measure: Exploratory Outcome - Pain Time: up to 12-weeksDescription: months
Measure: Exploratory Outcome - Diabetes duration Time: up to 12-weeksDescription: Diabetes Self-Management and Technology Questionnaire (DSMT-Q); Minimum score: 0; maximum score: 48; higher score represented a worse outcome.
Measure: Exploratory Outcome - Diabetes self-management Time: up to 12-weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports